Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.
Heslop
H E
HE
Brenner
M K
MK
Rooney
C
C
Krance
R A
RA
Roberts
W M
WM
Rochester
R
R
Smith
C A
CA
Turner
V
V
Sixbey
J
J
Moen
R
R
D000328:Adult; D015415:Biomarkers; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002460:Cell Line; D002648:Child; D002985:Clinical Protocols; D003602:Cytotoxicity, Immunologic; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D005822:Genetic Vectors; D006086:Graft vs Host Disease / Q000517:prevention & control; D006566:Herpesviridae Infections / Q000517:prevention & control* / Q000635:transmission; D004854:Herpesvirus 4, Human / Q000254:growth & development / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007258:Informed Consent; D019868:Kanamycin Kinase; D007938:Leukemia / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D008297:Male; D008979:Moloney murine leukemia virus / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000601:surgery; D009355:Neomycin / Q000494:pharmacology; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000096:biosynthesis / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics*; D012449:Safety; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology / Q000637:transplantation*; D014019:Tissue Donors; D014184:Transplantation, Homologous; D014412:Tumor Virus Infections / Q000517:prevention & control* / Q000635:transmission; D014775:Virus Activation / Q000276:immunology
D015415:Biomarkers; D011993:Recombinant Fusion Proteins; D017853:Phosphotransferases (Alcohol Group Acceptor); D019868:Kanamycin Kinase; D009355:Neomycin